We are conducting system maintenance, which may temporarily affect some services and our ability to answer phone calls. For urgent queries, please contact us via email using the addresses on our contact page. We appreciate your patience and are working to restore full services promptly. Thank you for your cooperation!
0
Signin
countryflagUS

18889881171

MSFT 416.9992 0.2113% AAPL 231.83 0.0216% NVDA 138.895 2.3394% GOOGL 163.53 -0.9869% GOOG 165.1 -0.9836% AMZN 187.78 0.4762% META 578.1245 0.2314% AVGO 183.5976 3.8331% TSLA 220.4371 -0.4034% TSM 207.9713 10.9299% LLY 917.515 -0.5652% V 289.845 0.8086% JPM 224.705 0.4762% UNH 568.2 -0.5496% NVO 118.43 0.3389% WMT 80.845 -0.4617% LVMUY 131.3 0.6439% XOM 120.36 -0.2486% LVMHF 659.0 1.0345% MA 513.11 -0.1867%

Molecular Templates Inc

Healthcare US MTEM

0.8196USD
0.49(152.11%)

Last update at 2024-10-17T18:50:00Z

Day Range

0.411.25
LowHigh

52 Week Range

1.169.45
LowHigh

Fundamentals

  • Previous Close 0.33
  • Market Cap8.23M
  • Volume194403469
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-16.34900M
  • Revenue TTM31.76M
  • Revenue Per Share TTM6.47
  • Gross Profit TTM -45.96800M
  • Diluted EPS TTM-4.61

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -92.66500M -83.00900M 104.91M -69.42100M -30.28700M
Minority interest - - - - -
Net income -92.71800M -79.31400M 104.92M -69.53700M -30.28700M
Selling general administrative 26.20M 34.11M 26.72M 20.08M 14.08M
Selling and marketing expenses - - - - -
Gross profit 19.75M 38.70M 18.84M 19.50M 13.29M
Reconciled depreciation 7.38M 6.63M 3.92M 1.18M 0.97M
Ebit -88.87100M -86.70400M 106.63M -70.44900M -31.22200M
Ebitda -87.88300M -80.07400M 110.54M -46.00300M -30.24800M
Depreciation and amortization 0.99M 6.63M 3.92M 24.45M 0.97M
Non operating income net other - - -3.39200M 0.00300M 0.95M
Operating income -88.87100M -80.07400M -100.84200M -70.44900M -30.99900M
Other operating expenses 108.62M 118.77M 119.69M 67.83M 38.28M
Interest expense 4.78M 3.37M 1.71M 1.30M 0.99M
Tax provision 0.05M 0.00000M 0.00500M - -
Interest income 0.99M 0.43M 1.03M 2.32M 0.75M
Net interest income -3.79400M -2.93500M -0.67700M 1.02M -0.23900M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.05M -3.69500M 0.00500M 0.12M 1.70M
Total revenue 19.75M 38.70M 18.84M 19.50M 7.28M
Total operating expenses 108.62M 118.77M 119.69M 67.83M 38.28M
Cost of revenue - - - 50.52M -6.00200M
Total other income expense net -3.79400M -2.93500M 205.75M 1.03M 0.95M
Discontinued operations - - - - -
Net income from continuing ops -92.71800M -83.00900M -104.91600M -69.42100M -30.28700M
Net income applicable to common shares -92.71800M -83.00900M -104.91600M -69.42100M -30.28700M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 35.38M 97.55M 192.36M 139.88M 174.20M
Intangible assets - - - - 1.20M
Earning assets - - - - -
Other current assets 5.00M 3.79M 1.25M 1.12M 0.49M
Total liab 31.17M 112.68M 126.70M 80.54M 71.17M
Total stockholder equity 4.21M -15.13200M 65.66M 59.34M 103.03M
Deferred long term liab - - 33.35M 4.54M 19.39M
Other current liab 4.28M 8.82M 9.52M 18.19M 2.50M
Common stock 0.00500M 0.06M 0.06M 0.05M 0.05M
Capital stock 0.00500M 0.06M 0.06M 0.05M 0.05M
Retained earnings -452.89200M -444.76800M -352.05000M -269.04100M -164.12500M
Other liab - 7.20M 34.98M 15.85M 20.75M
Good will - - - - -
Other assets 0.00000M 3.49M 7.24M 5.20M 3.48M
Cash 11.52M 32.19M 24.98M 25.22M 85.45M
Cash and equivalents - - - - -
Total current liabilities 17.32M 57.08M 46.67M 37.55M 35.80M
Current deferred revenue 9.03M 45.57M 32.94M 14.80M 17.29M
Net debt 0.71M 18.39M 20.07M 1.92M -70.82900M
Short term debt 2.49M 2.18M 2.61M 2.21M 14.54M
Short long term debt - - - - -
Short long term debt total 12.23M 50.58M 45.05M 27.14M 14.62M
Other stockholder equity 457.10M 429.65M 417.70M 328.31M 267.09M
Property plant equipment - 25.76M 19.31M 33.36M 18.16M
Total current assets 16.77M 68.30M 148.22M 101.32M 139.90M
Long term investments - 0.00000M 8.99M 0.00000M 1.51M
Net tangible assets - -15.13200M 65.66M 59.34M 103.03M
Short term investments 0.00000M 28.86M 118.06M 68.67M 39.63M
Net receivables 0.25M - 0.00000M 0.23M 7.51M
Long term debt - 36.17M 35.49M 14.93M 2.94M
Inventory - - - 6.08M 6.82M
Accounts payable 1.52M 0.50M 1.61M 2.35M 1.47M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - -0.06600M -0.04800M 0.02M 0.02M
Additional paid in capital - - - - -
Common stock total equity - - 0.06M 0.05M 0.05M
Preferred stock total equity - - - - -
Retained earnings total equity - - -352.05000M -269.04100M -164.12500M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.74M 3.49M 7.24M 5.20M 4.68M
Deferred long term asset charges - - - - -
Non current assets total 18.61M 29.25M 44.15M 38.55M 34.30M
Capital lease obligations 12.23M 14.41M 9.56M 14.42M 11.68M
Long term debt total - - 35.49M 14.93M 2.94M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 95.32M -58.44400M -34.66300M -30.07500M -10.22300M
Change to liabilities -15.91800M -4.49700M -13.73000M 7.15M 1.16M
Total cashflows from investing activities 95.32M -62.44000M -34.66300M -39.72400M -15.94500M
Net borrowings - 19.83M 9.48M 0.03M 0.89M
Total cash from financing activities -0.26500M 92.59M 58.90M 65.70M 49.22M
Change to operating activities -1.39600M -15.41600M 7.75M 8.95M 1.62M
Net income -92.71800M -83.00900M -104.91600M -69.42100M -30.28700M
Change in cash 6.03M -0.23500M -59.56500M 0.73M 28.81M
Begin period cash flow 28.65M 28.89M 88.45M 87.72M 58.91M
End period cash flow 34.68M 28.65M 28.89M 88.45M 87.72M
Total cash from operating activities -89.02400M -30.38700M -83.79700M -25.24400M -4.46500M
Issuance of capital stock 0.00000M 71.14M 48.37M 63.92M 48.05M
Depreciation 7.38M 6.63M 3.92M 1.18M 0.97M
Other cashflows from investing activities - - 0.01M -30.07500M -10.22300M
Dividends paid - - - - -
Change to inventory - -15.65900M 14.94M 3.37M -2.28500M
Change to account receivables 0.00000M 0.23M 0.17M -0.16800M -0.24000M
Sale purchase of stock - 72.77M 49.41M 65.67M 48.34M
Other cashflows from financing activities -0.26500M 21.45M 15.72M 1.81M 4.82M
Change to netincome 12.53M 17.07M 15.33M 28.00M 3.07M
Capital expenditures 3.20M 4.00M 7.39M 9.65M 5.72M
Change receivables - 0.23M 0.17M -0.16800M -0.24000M
Cash flows other operating - 32.31M 5.57M 7.46M 20.51M
Exchange rate changes - - - - -
Cash and cash equivalents changes - -0.23500M -59.56500M 0.73M 28.81M
Change in working capital -17.31400M 27.90M 1.30M 14.44M 21.43M
Stock based compensation 11.91M 16.63M 11.82M 5.86M 3.99M
Other non cash items 1.72M 1.02M 0.68M 0.56M 0.23M
Free cash flow -92.22200M -34.38300M -91.18900M -34.89300M -10.18700M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
MTEM
Molecular Templates Inc		 0.49 152.11% 0.82 - - 0.22 2.95 0.25 11.30
NVO
Novo Nordisk A/S		 0.40 0.34% 118.43 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 2.04 1.75% 118.30 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 11.16 2.29% 498.42 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -6.665 0.66% 1001.29 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.

Molecular Templates Inc

9301 Amberglen Boulevard, Austin, TX, United States, 78729

Key Executives

Name Title Year Born
Dr. Eric E. Poma Ph.D. CEO, Chief Scientific Officer & Director 1972
Ms. Jason S Kim Pres & COO 1975
Dr. Roger J. Waltzman M.B.A., M.D. Chief Medical Officer 1968
Mr. Sean McLennan Sr. VP of Fin., Controller, Interim Principal Accounting Officer, Interim CFO & Treasurer 1970
Ms. Megan C. Filoon Gen. Counsel & Sec. NA
Mr. Kurt Elster Exec. VP of Corp. Devel. 1967
Dr. Jack Higgins Ph.D. Exec. VP of Operations & Head of Manufacturing 1980
Dr. Erin Willert Ph.D. Exec. VP of R&D 1982
Dr. Jen-Sing Liu Ph.D. Exec. VP of Manufacturing 1963
Mr. Michael Dowd Sr. VP of Project & Alliance Management NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.